47 results on '"Collotta D"'
Search Results
2. FROM PRECLINICAL TO CLINICAL EVIDENCE: EXPLORING THE MULTIPLE PERSPECTIVES AND HEALING POWER OF BOSWELLIA SERRATA ROXB. EX COLEBR
- Author
-
Biagi, M., primary, Sarill, M., additional, Collotta, D., additional, Di Giacomo, S., additional, Di Sotto, A., additional, Grilli, M., additional, Luceri, C., additional, Milella, L., additional, Sangiovanni, E., additional, Vitalone, A., additional, Montopoli, M., additional, and Testai, L., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Different impact of dietary fructose and galactose on metaflammation in rats: protective effects of prebiotic fructooligosaccharydes supplementation
- Author
-
Mastrocola, R, Collotta, D, El-Masri, F, Murzio, C, Aimaretti, E, Aragno, M, Frank, J, and Collino, M
- Published
- 2022
4. Anti-inflammatory and anti-glycative properties of zinc-enriched spirulina in diet-induced obese/diabetic mice
- Author
-
Aimaretti, E, Murzio, C, Ferreira Alves, G, Einaudi, G, Collotta, D, Porchietto, E, Cifani, C, Algeri, A, Aragno, M, Collino, M, and Mastrocola, R
- Subjects
Physiology (medical) ,Biochemistry - Published
- 2022
5. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades
- Author
-
Penna C., Aragno M., Cento A. S., Femmino S., Russo I., Bello F. D., Chiazza F., Collotta D., Alves G. F., Bertinaria M., Zicola E., Mercurio V., Medana C., Collino M., Pagliaro P., Penna, C., Aragno, M., Cento, A. S., Femmino, S., Russo, I., Bello, F. D., Chiazza, F., Collotta, D., Alves, G. F., Bertinaria, M., Zicola, E., Mercurio, V., Medana, C., Collino, M., and Pagliaro, P.
- Abstract
Inhibition of either P2Y12 receptor or the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain containing 3 (NLRP3) inflammasome provides cardioprotective effects. Here, we investigate whether direct NLRP3 inflammasome inhibition exerts additive effects on myocardial protection induced by the P2Y12 receptor antagonist Ticagrelor. Ticagrelor (150 mg/kg) was orally administered to rats for three consecutive days. Then, isolated hearts underwent an ischemia/reperfusion (30 min ischemia/60 min reperfusion; IR) protocol. The selective NLRP3 inflammasome inhibitor INF (50 μM) was infused before the IR protocol to the hearts from untreated animals or pretreated with Ticagrelor. In parallel experiments, the hearts isolated from untreated animals were perfused with Ticagrelor (3.70 μM) before ischemia and subjected to IR. The hearts of animals pretreated with Ticagrelor showed a significantly reduced infarct size (IS, 49±3% of area at risk, AAR) when compared to control IR group (69±2% of AAR). Similarly, ex vivo administration of INF before the IR injury resulted in significant IS reduction (38±3% of AAR). Myocardial IR induced the NLRP3 inflammasome complex formation, which was attenuated by either INF pretreatment ex vivo, or by repeated oral treatment with Ticagrelor. The beneficial effects induced by either treatment were associated with the protective Reperfusion Injury Salvage Kinase (RISK) pathway activation and redox defence upregulation. In contrast, no protective effects nor NLRP3/RISK modulation were recorded when Ticagrelor was administered before ischemia in isolated heart, indicating that Ticagrelor direct target is not in the myocardium. Our results confirm that Ticagrelor conditioning effects are likely mediated through platelets, but are not additives to the ones achieved by directly inhibiting NLRP3.
- Published
- 2020
6. A retrospective analysis on pharmacological approaches to COVID-19 patients in an Italian hub hospital during the early phase of the pandemic
- Author
-
Menardi, G., primary, Infante, L., additional, Del Bono, V., additional, Fenoglio, L., additional, Collotta, D., additional, Macagno, P., additional, Bedogni, C., additional, Rebora, M., additional, Fruttero, C., additional, and Collino, M., additional
- Published
- 2021
- Full Text
- View/download PDF
7. Inhibition of Bruton's tyrosine kinase regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation
- Author
-
Purvis, GSD, Collino, M, Aranda-Tavio, H, Chiazza, F, O'Riordan, CE, Zeboudj, L, Mohammad, S, Collotta, D, Verta, R, Guisot, NES, Bunyard, P, Yaqoob, MM, Greaves, DR, and Thiemermann, C
- Abstract
Background and Purpose Currently there are limited medicines available for the treatment of metabolic inflammation in diseases such as obesity and type 2 diabetes (T2D). Although initially associated with B‐ells, Bruton's tyrosine kinase (BTK) is present in a wide variety of cells including monocytes and macrophages, and has been implicated in the regulation of the NF‐κB and NLRP3 inflammasome activity. Experimental Approach Using in vivo models of chronic inflammation [high‐fat‐diet (HFD) feeding] and in vitro assays in primary murine and human macrophages we investigated if ibrutinib, an FDA approved medicine that targets BTK, may represent a novel anti‐inflammatory drug for the use in treating metabolic inflammation. Key results HFD feeding was associated with increased BTK expression and activation, which was significantly correlated with monocyte/macrophage accumulation in the liver, adipose tissue and kidney. Treatment of mice fed HFD with ibrutinib inhibited the activation of BTK and reduced monocyte/macrophage recruitment to the liver, adipose tissue and kidney. Reduced inflammatory gene expression associated with decreased activation of NF‐κB and the NLRP3 inflammasome in vivo. As a result, ibrutinib treated mice fed HFD had improved glycaemic control through restored signalling by the IRS‐1/Akt/GSK‐3β pathway; protecting mice against the development of hepatosteatosis and proteinuria. We show that inhibition of BTK reduces activation of NF‐κB and the NLRP3 inflammasome specifically in primary murine and human macrophages; which are the primary target of ibrutinib in vivo in the setting of metabolic inflammation. Conclusions and Implications In the present study we provide ‘proof of concept' evidence that BTK is a novel therapeutic target for the treatment of diet ‐metabolic inflammation. Ibrutinib may be a candidate for drug repurposing as an anti‐inflammatory for the treatment of metabolic inflammation in T2D and microvascular disease.
- Published
- 2020
8. Dietary advanced glycation endproducts in the mechanisms linking proteins glycosylation pattern, microbiota, and metabolic inflammation
- Author
-
Mastrocola, R., Collotta, D., Manig, F., Verta, R., Le Berre, M., Fava, F., Gaudioso, G., Aragno, M., Chiazza, F., Hellwig, M., Gerlach, J. Q., Kieran Tuohy, Joshi, L., Henle, T., and Collino, M.
- Published
- 2020
9. Baricitinib counteracts metaflammation protecting against diet-induced metabolic abnormalities in mice
- Author
-
Collotta, D, Hull, W, Mastrocola, R, Chiazza, F, Cento, As, Murphy, C, Verta, R, Ferreira Alves, G, Gaudioso, G, Fava, F, Aragno, M, Tuohy, K, Thiemermann, C, and Collino, M
- Published
- 2020
10. Cold ischemic injury is reduced by the mGluR5 negative allosteric modulator MPEP in rat livers from cardiac death donors
- Author
-
Berardo, C., primary, Verta, R., additional, Di Pasqua, L.G., additional, Collotta, D., additional, Siciliano, V., additional, Nicoletti, F., additional, Vairetti, M., additional, Collino, M., additional, and Ferrigno, A., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Inhibition of AGEs by pyridoxamine prevents diet-induced systemic inflammation and skeletal muscle insulin resistance by restoring SphK/S1P3/RhoA signalling
- Author
-
Cento, As, Collotta, D, Chiazza, F, Aragno, M, Collino, M, and Mastrocola, R
- Published
- 2019
12. AGEs induce alterations of sphingolipids metabolism in the liver of genetically- and diet-induced diabetic mice
- Author
-
Cento, As, Gaens, K, Collotta, D, Chiazza, F, Barutta, F, Scheijen, J, Aragno, M, Collino, M, Wouters, K, Schalkwijk, Cg, and Mastrocola, R
- Published
- 2018
13. The AGEs inhibitor pyridoxamine prevents kidney injury and dysfunction in mice fed high-fat high-fructose diet
- Author
-
Collino, M., Fausto Chiazza, Collotta, D., Cento, As, Nigro, D., Bitonto, V., Cutrin, Jc, Aragno, M., and Mastrocola, R.
- Published
- 2017
14. Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction
- Author
-
Chiazza, F., primary, Cento, A. S., additional, Collotta, D., additional, Nigro, D., additional, Rosa, G., additional, Baratta, F., additional, Bitonto, V., additional, Cutrin, J. C., additional, Aragno, M., additional, Mastrocola, R., additional, and Collino, M., additional
- Published
- 2017
- Full Text
- View/download PDF
15. Identification of Annexina1 as an endogenous regulator of RhoA, and its role in the pathophysiology and experimental therapy of type-2 diabetes
- Author
-
Gareth S D, Purvis, Massimo, Collino, Rodrigo A, Loiola, Andrea, Baragetti, Fausto, Chiazza, Martina, Brovelli, Madeeha H, Sheikh, Debora, Collotta, Alessia, Cento, Raffaella, Mastrocola, Manuela, Aragno, Juan C, Cutrin, Chris, Reutelingsperger, Liliana, Grigore, Alberico L, Catapano, Magdi M, Yaqoob, Giuseppe Danilo, Norata, Egle, Solito, Christoph, Thiemermann, Purvis, G. S. D., Collino, M., Loiola, R. A., Baragetti, A., Chiazza, F., Brovelli, M., Sheikh, M. H., Collotta, D., Cento, A., Mastrocola, R., Aragno, M., Cutrin, J. C., Reutelingsperger, C., Grigore, L., Catapano, A. L., Yaqoob, M. M., Norata, G. D., Solito, E., Thiemermann, C., RS: CARIM - R1 - Thrombosis and haemostasis, Biochemie, and RS: Carim - B02 Vascular aspects thrombosis and Haemostasis
- Subjects
endocrine system ,kinase inhibitor ,METFORMIN ,Immunology ,PROGRESSION ,Diet, High-Fat ,Diabetes Mellitus, Experimental ,statins ,MECHANISMS ,PROTECTS ,Mice ,hepatosteatosis ,Animals ,Humans ,Obesity ,Annexin A1 ,Hepatosteatosis ,Metabolism ,Nephropathy ,Rho A ,Type-2 diabetes ,GLUCOCORTICOIDS ,Receptors, Lipoxin ,A1 ,Dyslipidemias ,Original Research ,Mice, Knockout ,cardiac dysfunction ,Receptors, Formyl Peptide ,Fatty Liver ,Mice, Inbred C57BL ,Cholesterol ,Diabetes Mellitus, Type 2 ,Hyperglycemia ,Insulin Receptor Substrate Proteins ,Hepatosteatosi ,Insulin Resistance ,rhoA GTP-Binding Protein - Abstract
Annexin A1 (ANXA1) is an endogenously produced anti-inflammatory protein, which plays an important role in the pathophysiology of diseases associated with chronic inflammation. We demonstrate that patients with type-2 diabetes have increased plasma levels of ANXA1 when compared to normoglycemic subjects. Plasma ANXA1 positively correlated with fatty liver index and elevated plasma cholesterol in patients with type-2 diabetes, suggesting a link between aberrant lipid handling, and ANXA1. Using a murine model of high fat diet (HFD)-induced insulin resistance, we then investigated (a) the role of endogenous ANXA1 in the pathophysiology of HFD-induced insulin resistance using ANXA1−/−mice, and (b) the potential use of hrANXA1 as a new therapeutic approach for experimental diabetes and its microvascular complications. We demonstrate that: (1) ANXA1−/−mice fed a HFD have a more severe diabetic phenotype (e.g., more severe dyslipidemia, insulin resistance, hepatosteatosis, and proteinuria) compared to WT mice fed a HFD; (2) treatment of WT-mice fed a HFD with hrANXA1 attenuated the development of insulin resistance, hepatosteatosis and proteinuria. We demonstrate here for the first time that ANXA1−/−mice have constitutively activated RhoA. Interestingly, diabetic mice, which have reduced tissue expression of ANXA1, also have activated RhoA. Treatment of HFD-mice with hrANXA1 restored tissue levels of ANXA1 and inhibited RhoA activity, which, in turn, resulted in restoration of the activities of Akt, GSK-3β and endothelial nitric oxide synthase (eNOS) secondary to re-sensitization of IRS-1 signaling. We further demonstrate in human hepatocytes that ANXA1 protects against excessive mitochondrial proton leak by activating FPR2 under hyperglycaemic conditions. In summary, our data suggest that (a) ANXA1 is a key regulator of RhoA activity, which restores IRS-1 signal transduction and (b) recombinant human ANXA1 may represent a novel candidate for the treatment of T2D and/or its complications.
- Published
- 2019
16. Anti-Glycation Properties of Zinc-Enriched Arthrospira platensis (Spirulina) Contribute to Prevention of Metaflammation in a Diet-Induced Obese Mouse Model.
- Author
-
Aimaretti E, Porchietto E, Mantegazza G, Gargari G, Collotta D, Einaudi G, Ferreira Alves G, Marzani E, Algeri A, Dal Bello F, Aragno M, Cifani C, Guglielmetti S, Mastrocola R, and Collino M
- Subjects
- Male, Mice, Animals, Mice, Obese, Zinc, RNA, Ribosomal, 16S, Mice, Inbred C57BL, Obesity etiology, Obesity metabolism, Diet, High-Fat adverse effects, Disease Models, Animal, Spirulina chemistry
- Abstract
Advanced glycation end products (AGEs) exert a key pathogenic role in the development of obesity and insulin resistance. Thanks to its abundance in bioactive compounds, the microalga Arthrospira platensis (spirulina, SP) is proposed as a nutritional supplement. Here, we investigated the potential anti-glycating properties of SP enriched with zinc (Zn-SP) and the following impact on diet-induced metabolic derangements. Thirty male C57Bl6 mice were fed a standard diet (SD) or a high-fat high-sugar diet (HFHS) for 12 weeks, and a subgroup of HFHS mice received 350 mg/kg Zn-SP three times a week. A HFHS diet induced obesity and glucose intolerance and increased plasma levels of pro-inflammatory cytokines and transaminases. Zn-SP administration restored glucose homeostasis and reduced hepatic dysfunction and systemic inflammation. In the liver of HFHS mice, a robust accumulation of AGEs was detected, paralleled by increased expression of the main AGE receptor (RAGE) and depletion of glyoxalase-1, whereas Zn-SP administration efficiently prevented these alterations reducing local pro-inflammatory responses. 16S rRNA gene profiling of feces and ileum content revealed altered bacterial community structure in HFHS mice compared to both SD and HFHS + Zn-SP groups. Overall, our study demonstrates relevant anti-glycation properties of Zn-SP which contribute to preventing AGE production and/or stimulate AGE detoxification, leading to the improvement of diet-related dysbiosis and metabolic derangements.
- Published
- 2024
- Full Text
- View/download PDF
17. Dietary Intake of Fructooligosaccharides Protects against Metabolic Derangements Evoked by Chronic Exposure to Fructose or Galactose in Rats.
- Author
-
Almasri F, Collotta D, Aimaretti E, Sus N, Aragno M, Dal Bello F, Eva C, Mastrocola R, Landberg R, Frank J, and Collino M
- Subjects
- Rats, Male, Animals, Galactose, Rats, Sprague-Dawley, Eating, Inflammation prevention & control, Diet, High-Fat adverse effects, Fructose adverse effects, Metabolic Diseases, Oligosaccharides
- Abstract
Scope: Diets rich in fat and sugars evoke chronic low-grade inflammation, leading to metabolic derangements. This study investigates the impact of fructose and galactose, two commonly consumed simple sugars, on exacerbation of the harmful effects caused by high fat intake. Additionally, the potential efficacy of fructooligosaccharides (FOS), a fermentable dietary fiber, in counteracting these effects is examined., Methods and Results: Male Sprague-Dawley rats (six/group) are fed 8 weeks as follows: control 5% fat diet (CNT), 20% fat diet (FAT), FAT+10% FOS diet (FAT+FOS), FAT+25% galactose diet (FAT+GAL), FAT+GAL+10% FOS diet (FAT+GAL+FOS), FAT+25% fructose diet (FAT+FRU), FAT+FRU+10% FOS diet (FAT+FRU+FOS). The dietary manipulations tested do not affect body weight gain, blood glucose, or markers of systemic inflammation whereas significant increases in plasma concentrations of triacylglycerols, cholesterol, aspartate aminotransferase, and alanine aminotrasferase are detected in both FAT+FRU and FAT+GAL compared to CNT. In the liver and skeletal muscle, both sugars induce significant accumulation of lipids and advanced glycation end-products (AGEs). FOS supplementation prevents these impairments., Conclusion: This study extends the understanding of the deleterious effects of a chronic intake of simple sugars and demonstrates the beneficial role of the prebiotic FOS in dampening the sugar-induced metabolic impairments by prevention of lipid and AGEs accumulation., (© 2023 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
18. [Exploring Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity: An Emerging Issue from Bench to Bedside].
- Author
-
Collotta D, Aimaretti E, and Collino M
- Subjects
- Humans, Tyrosine Kinase Inhibitors, Protein Kinase Inhibitors adverse effects
- Abstract
Tyrosine Kinase Inhibitors (TKIs) have significantly contributed to revolutionizing cancer treatment, as they are orally administered small molecules able to target key pathways involved in tumor growth and angiogenesis. However, the clinical utility of TKIs may be compromised by adverse effects, which can affect tissues and organs, including kidneys. This comprehensive review offers a general overview of studies reporting the incidence and clinical characteristics of TKI-related nephrotoxicity and it explores the mechanisms underlying the intricate relationship between TKIs and renal toxicity. The biological rationale for the kidney manifestations of toxicity associated with TKI agents is here discussed, underlying potential off-target effects and emphasizing the importance of accurate risk assessment and tailored patient management strategies. Deep insight into the molecular mechanisms of TKI nephrotoxicity will help to improve the global understanding of the pathophysiology of this peculiar toxicity and to develop more effective and safer therapies., (Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.)
- Published
- 2023
19. Recent advances in JAK inhibitors for the treatment of metabolic syndrome.
- Author
-
Collotta D, Franchina MP, Carlucci V, and Collino M
- Abstract
With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around the waist and abnormal cholesterol or triglyceride levels. These conditions lead directly to several disorders, including obesity, dyslipidemia, hyperglycaemia, insulin resistance, impaired glucose tolerance and hypertension causing an increase in cardiovascular risk and in particular atherosclerotic disease. Despite efforts to promote healthier lifestyles through exercise, reduced caloric intake, and improved dietary choices, the incidence and prevalence of metabolic syndrome continue to rise worldwide. Recent research has highlighted the involvement of signaling pathways in chronic inflammatory conditions like obesity and type 2 diabetes mellitus, revealing the significance of the JAK/STAT pathway in atherosclerotic events. This pathway serves as a rapid membrane-to-nucleus signaling module that regulates the expression of critical mediators. Consequently, JAK inhibitors (JAKi) have emerged as potential therapeutic options for metabolic diseases, offering a promising avenue for intervention. The aim of this review is to shed light on the emerging indications of JAK inhibitors in metabolic syndrome, emphasizing their potential role in attenuating associated inflammatory processes, improving insulin sensitivity, and addressing cross-talk with the insulin pathway, with the intention of contributing to efforts in the field of inflammation pharmacology., Competing Interests: VC was employed by Chemsafe S.r.l., a consultancy firm in the pharma field. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Collotta, Franchina, Carlucci and Collino.)
- Published
- 2023
- Full Text
- View/download PDF
20. Editorial: The challenges of drug repurposing in diseases related to chronic inflammation.
- Author
-
Collotta D and Lucarini L
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
21. Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats.
- Author
-
Patel NM, Collotta D, Aimaretti E, Ferreira Alves G, Kröller S, Coldewey SM, Collino M, and Thiemermann C
- Subjects
- Rats, Animals, NF-kappa B metabolism, NF-kappa B pharmacology, Janus Kinases metabolism, Janus Kinases pharmacology, Multiple Organ Failure etiology, Multiple Organ Failure prevention & control, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, STAT Transcription Factors metabolism, STAT Transcription Factors pharmacology, Signal Transduction, Shock, Hemorrhagic complications, Shock, Hemorrhagic drug therapy
- Abstract
Objective: The aim of this study was to investigate (a) the effects of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway inhibitor (baricitinib) on the multiple organ dysfunction syndrome (MODS) in a rat model of hemorrhagic shock (HS) and (b) whether treatment with baricitinib attenuates the activation of JAK/STAT, NF-κB, and NLRP3 caused by HS., Background: Posttraumatic MODS, which is in part due to excessive systemic inflammation, is associated with high morbidity and mortality. The JAK/STAT pathway is a regulator of numerous growth factor and cytokine receptors and, hence, is considered a potential master regulator of many inflammatory signaling processes. However, its role in trauma-hemorrhage is unknown., Methods: An acute HS rat model was performed to determine the effect of baricitinib on MODS. The activation of JAK/STAT, NF-κB, and NLRP3 pathways were analyzed by western blotting in the kidney and liver., Results: We demonstrate here for the first time that treatment with baricitinib (during resuscitation following severe hemorrhage) attenuates the organ injury and dysfunction and the activation of JAK/STAT, NF-κB, and NLRP3 pathways caused by HS in the rat., Conclusions: Our results point to a role of the JAK/STAT pathway in the pathophysiology of the organ injury and dysfunction caused by trauma/hemorrhage and indicate that JAK inhibitors, such as baricitinib, may be repurposed for the treatment of the MODS after trauma and/or hemorrhage., Competing Interests: The authors report no conflicts of interest., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
22. Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery.
- Author
-
Collotta D, Colletta S, Carlucci V, Fruttero C, Fea AM, and Collino M
- Abstract
Glaucoma is an acquired optic neuropathy that results in a characteristic optic nerve head appearance and visual field loss. Reducing the IOP is the only factor that can be modified, and the progression of the disease can be managed through medication, laser treatment, or surgery. Filtering procedures are used when target pressure cannot be obtained with less invasive methods. Nevertheless, these procedures require accurate control of the fibrotic process, which can hamper filtration, thus, negatively affecting the surgical success. This review explores the available and potential pharmacological treatments that modulate the scarring process after glaucoma surgery, analyzing the most critical evidence available in the literature. The modulation of scarring is based on non-steroidal anti-inflammatory drugs (NSAIDs), mitomycin, and 5-fluorouracil. In the long term, the failure rate of filtering surgery is mainly due to the limitations of the current strategies caused by the complexity of the fibrotic process and the pharmacological and toxicological aspects of the drugs that are currently in use. Considering these limitations, new potential treatments were investigated. This review suggests that a better approach to tackle the fibrotic process may be to hit multiple targets, thus increasing the inhibitory potential against excessive scarring following surgery.
- Published
- 2023
- Full Text
- View/download PDF
23. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
- Author
-
Alves GF, Stoppa I, Aimaretti E, Monge C, Mastrocola R, Porchietto E, Einaudi G, Collotta D, Bertocchi I, Boggio E, Gigliotti CL, Clemente N, Aragno M, Fernandes D, Cifani C, Thiemermann C, Dianzani C, Dianzani U, and Collino M
- Subjects
- Animals, Male, Mice, Creatinine, Cytokines metabolism, Immune Checkpoint Proteins, Immunity, Immunomodulation, Inducible T-Cell Co-Stimulator Ligand genetics, Inducible T-Cell Co-Stimulator Ligand metabolism, Inducible T-Cell Co-Stimulator Protein genetics, Inflammasomes, Inflammation, Interleukin-10, Interleukin-6, Ligands, Mice, Inbred C57BL, Mice, Knockout, NLR Family, Pyrin Domain-Containing 3 Protein, p38 Mitogen-Activated Protein Kinases, Tumor Necrosis Factor-alpha, Urea, Osteopontin, Sepsis drug therapy
- Abstract
Inducible T cell co-stimulator (ICOS), an immune checkpoint protein expressed on activated T cells and its unique ligand, ICOSL, which is expressed on antigen-presenting cells and non-hematopoietic cells, have been extensively investigated in the immune response. Recent findings showed that a soluble recombinant form of ICOS (ICOS-Fc) can act as an innovative immunomodulatory drug as both antagonist of ICOS and agonist of ICOSL, modulating cytokine release and cell migration to inflamed tissues. Although the ICOS-ICOSL pathway has been poorly investigated in the septic context, a few studies have reported that septic patients have reduced ICOS expression in whole blood and increased serum levels of osteopontin (OPN), that is another ligand of ICOSL. Thus, we investigated the pathological role of the ICOS-ICOSL axis in the context of sepsis and the potential protective effects of its immunomodulation by administering ICOS-Fc in a murine model of sepsis. Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in five-month-old male wild-type (WT) C57BL/6, ICOS
-/- , ICOSL-/- and OPN-/- mice. One hour after the surgical procedure, either CLP or Sham (control) mice were randomly assigned to receive once ICOS-Fc,F119S ICOS-Fc, a mutated form uncapable to bind ICOSL, or vehicle intravenously. Organs and plasma were collected 24 h after surgery for analyses. When compared to Sham mice, WT mice that underwent CLP developed within 24 h a higher clinical severity score, a reduced body temperature, an increase in plasma cytokines (TNF-α, IL-1β, IL-6, IFN-γ and IL-10), liver injury (AST and ALT) and kidney (creatinine and urea) dysfunction. Administration of ICOS-Fc to WT CLP mice reduced all of these abnormalities caused by sepsis. Similar beneficial effects were not seen in CLP-mice treated withF119S ICOS-Fc. Treatment of CLP-mice with ICOS-Fc also attenuated the sepsis-induced local activation of FAK, P38 MAPK and NLRP3 inflammasome. ICOS-Fc seemed to act at both sides of the ICOS-ICOSL interaction, as the protective effect was lost in septic knockout mice for the ICOS or ICOSL genes, whereas it was maintained in OPN knockout mice. Collectively, our data show the beneficial effects of pharmacological modulation of the ICOS-ICOSL pathway in counteracting the sepsis-induced inflammation and organ dysfunction., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Alves, Stoppa, Aimaretti, Monge, Mastrocola, Porchietto, Einaudi, Collotta, Bertocchi, Boggio, Gigliotti, Clemente, Aragno, Fernandes, Cifani, Thiemermann, Dianzani, Dianzani and Collino.)- Published
- 2022
- Full Text
- View/download PDF
24. Inhibition of Macrophage Migration Inhibitory Factor Activity Attenuates Haemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.
- Author
-
Patel NM, Yamada N, Oliveira FRMB, Stiehler L, Zechendorf E, Hinkelmann D, Kraemer S, Stoppe C, Collino M, Collotta D, Alves GF, Ramos HP, Sordi R, Marzi I, Relja B, Marx G, Martin L, and Thiemermann C
- Subjects
- Animals, Humans, Multiple Organ Failure etiology, Multiple Organ Failure prevention & control, NF-kappa B metabolism, NLR Family, Pyrin Domain-Containing 3 Protein, Rats, Macrophage Migration-Inhibitory Factors, Multiple Trauma complications, Shock, Hemorrhagic complications, Shock, Hemorrhagic drug therapy
- Abstract
Objective: The aim of this study was to investigate (a) macrophage migration inhibitory factor (MIF) levels in polytrauma patients and rats after haemorrhagic shock (HS), (b) the potential of the MIF inhibitor ISO-1 to reduce multiple organ dysfunction syndrome (MODS) in acute (short-term and long-term follow-up) HS rat models and (c) whether treatment with ISO-1 attenuates NF-κB and NLRP3 activation in HS., Background: The MODS caused by an excessive systemic inflammatory response following trauma is associated with a high morbidity and mortality. MIF is a pleiotropic cytokine which can modulate the inflammatory response, however, its role in trauma is unknown., Methods: The MIF levels in plasma of polytrauma patients and serum of rats with HS were measured by ELISA. Acute HS rat models were performed to determine the influence of ISO-1 on MODS. The activation of NF-κB and NLRP3 pathways were analysed by western blot in the kidney and liver., Results: We demonstrated that (a) MIF levels are increased in polytrauma patients on arrival to the emergency room and in rats after HS, (b) HS caused organ injury and/or dysfunction and hypotension (post-resuscitation) in rats, while (c) treatment of HS-rats with ISO-1 attenuated the organ injury and dysfunction in acute HS models and (d) reduced the activation of NF-κB and NLRP3 pathways in the kidney and liver., Conclusion: Our results point to a role of MIF in the pathophysiology of trauma-induced organ injury and dysfunction and indicate that MIF inhibitors may be used as a potential therapeutic approach for MODS after trauma and/or haemorrhage., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Patel, Yamada, Oliveira, Stiehler, Zechendorf, Hinkelmann, Kraemer, Stoppe, Collino, Collotta, Alves, Ramos, Sordi, Marzi, Relja, Marx, Martin and Thiemermann.)
- Published
- 2022
- Full Text
- View/download PDF
25. Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice.
- Author
-
Alves GF, Aimaretti E, Einaudi G, Mastrocola R, de Oliveira JG, Collotta D, Porchietto E, Aragno M, Cifani C, Sordi R, Thiemermann C, Fernandes D, and Collino M
- Subjects
- Animals, Cytokines metabolism, Disease Models, Animal, Inflammation physiopathology, Ligation, Male, Mice, Mice, Inbred C57BL, Multiple Organ Failure drug therapy, Multiple Organ Failure physiopathology, Random Allocation, Sepsis, Survival Rate, Focal Adhesion Kinase 1 antagonists & inhibitors, Focal Adhesion Kinase 2 antagonists & inhibitors, Inflammation drug therapy, Mitogen-Activated Protein Kinases antagonists & inhibitors, Protein Kinase Inhibitors pharmacology
- Abstract
Sepsis and septic shock are associated with high mortality and are considered one of the major public health concerns. The onset of sepsis is known as a hyper-inflammatory state that contributes to organ failure and mortality. Recent findings suggest a potential role of two non-receptor protein tyrosine kinases, namely Focal adhesion kinase (FAK) and Proline-rich tyrosine kinase 2 (Pyk2), in the inflammation associated with endometriosis, cancer, atherosclerosis and asthma. Here we investigate the role of FAK-Pyk2 in the pathogenesis of sepsis and the potential beneficial effects of the pharmacological modulation of this pathway by administering the potent reversible dual inhibitor of FAK and Pyk2, PF562271 (PF271) in a murine model of cecal ligation and puncture (CLP)-induced sepsis. Five-month-old male C57BL/6 mice underwent CLP or Sham surgery and one hour after the surgical procedure, mice were randomly assigned to receive PF271 (25 mg/kg, s.c.) or vehicle. Twenty-four hours after surgery, organs and plasma were collected for analyses. In another group of mice, survival rate was assessed every 12 h over the subsequent 5 days. Experimental sepsis led to a systemic cytokine storm resulting in the formation of excessive amounts of both pro-inflammatory cytokines (TNF-α, IL-1β, IL-17 and IL-6) and the anti-inflammatory cytokine IL-10. The systemic inflammatory response was accompanied by high plasma levels of ALT, AST (liver injury), creatinine, (renal dysfunction) and lactate, as well as a high, clinical severity score. All parameters were attenuated following PF271 administration. Experimental sepsis induced an overactivation of FAK and Pyk2 in liver and kidney, which was associated to p38 MAPK activation, leading to increased expression/activation of several pro-inflammatory markers, including the NLRP3 inflammasome complex, the adhesion molecules ICAM-1, VCAM-1 and E-selectin and the enzyme NOS-2 and myeloperoxidase. Treatment with PF271 inhibited FAK-Pyk2 activation, thus blunting the inflammatory abnormalities orchestrated by sepsis. Finally, PF271 significantly prolonged the survival of mice subjected to CLP-sepsis. Taken together, our data show for the first time that the FAK-Pyk2 pathway contributes to sepsis-induced inflammation and organ injury/dysfunction and that the pharmacological modulation of this pathway may represents a new strategy for the treatment of sepsis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Alves, Aimaretti, Einaudi, Mastrocola, de Oliveira, Collotta, Porchietto, Aragno, Cifani, Sordi, Thiemermann, Fernandes and Collino.)
- Published
- 2022
- Full Text
- View/download PDF
26. Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems.
- Author
-
Wouters K, Cento AS, Gaens KH, Teunissen M, Scheijen JLJM, Barutta F, Chiazza F, Collotta D, Aragno M, Gruden G, Collino M, Schalkwijk CG, and Mastrocola R
- Subjects
- Adipose Tissue metabolism, Animals, Female, Gene Deletion, Inflammasomes, Inflammation metabolism, Lipids chemistry, Liver metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Obese, Receptors, Immunologic metabolism, Signal Transduction, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease prevention & control, Receptor for Advanced Glycation End Products genetics, Receptor for Advanced Glycation End Products physiology
- Abstract
Advanced glycation endproducts (AGEs) are involved in several diseases, including NAFLD and NASH. RAGE is the main receptor mediating the pro-inflammatory signalling induced by AGEs. Therefore, targeting of RAGE has been proposed for prevention of chronic inflammatory diseases. However, the role of RAGE in the development of NAFLD and NASH remains poorly understood. We thus aimed to analyse the effect of obesity on AGEs accumulation, AGE-receptors and AGE-detoxification, and whether the absence of RAGE might improve hepatosteatosis and inflammation, by comparing the liver of lean control, obese (LeptrDb-/-) and obese RAGE-deficient (RAGE-/- LeptrDb-/-) mice. Obesity induced AGEs accumulation and RAGE expression with hepatosteatosis and inflammation in LeptrDb-/-, compared to lean controls. Despite the genetic deletion of RAGE in the LeptrDb-/- mice, high levels of intrahepatic AGEs were maintained accompanied by decreased expression of the protective AGE-receptor-1, impaired AGE-detoxifying system glyoxalase-1, and increased expression of the alternative AGE-receptor galectin-3. We also found sustained hepatosteatosis and inflammation as determined by persistent activation of the lipogenic SREBP1c and proinflammatory NLRP3 signalling pathways. Thus, RAGE targeting is not effective in the prevention of NAFLD in conditions of obesity, likely due to the direct liver specific crosstalk of RAGE with other AGE-receptors and AGE-detoxifying systems., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
27. In Vitro Evaluation of the Toxicological Profile and Oxidative Stress of Relevant Diet-Related Advanced Glycation End Products and Related 1,2-Dicarbonyls.
- Author
-
Cepas V, Manig F, Mayo JC, Hellwig M, Collotta D, Sanmartino V, Carrocera-Pumarino R, Collino M, Henle T, and Sainz RM
- Subjects
- Deoxyglucose adverse effects, Deoxyglucose analogs & derivatives, Galactose adverse effects, Galactose analogs & derivatives, Humans, In Vitro Techniques, Inflammation immunology, Inflammation metabolism, Inflammation pathology, Keratinocytes drug effects, Keratinocytes immunology, Keratinocytes metabolism, NF-kappa B metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Reactive Oxygen Species metabolism, Apoptosis, Glycation End Products, Advanced adverse effects, Inflammation drug therapy, Keratinocytes pathology, Oxidative Stress drug effects, Pyrones adverse effects
- Abstract
During food processing and storage, and in tissues and fluids under physiological conditions, the Maillard reaction occurs. During this reaction, reactive 1,2-dicarbonyl compounds arise as intermediates that undergo further reactions to form advanced glycation end products (AGEs). Diet is the primary source of exogenous AGEs. Endogenously formed AGEs have been proposed as a risk factor in the pathogenesis of diet-related diseases such as diabetes, insulin resistance, cardiovascular diseases, or chronic disease. AGEs may differently contribute to the diet-related exacerbation of oxidative stress, inflammation, and protein modifications. Here, to understand the contribution of each compound, we tested individually, for the first time, the effect of five 1,2-dicarbonyl compounds 3-deoxyglucosone (3-DG), 3-deoxygalactosone (3-DGal), 3,4-dideoxyglucosone-3-ene (3,4-DGE), glyoxal (GO), and methylglyoxal (MGO) and four different glycated amino acids N- ε -(carboxyethyl)lysine (CEL), N- ε -(carboxymethyl)lysine (CML), methylglyoxal-derived hydroimidazolone-1 (MG-H1), and pyrraline (Pyrr) in a cell line of human keratinocytes (HaCaT). We found that most of the glycated amino acids, i.e., CEL, CML, and MG-H1, did not show any cytotoxicity. At the same time, 1,2-dicarbonyl compounds 3-DGal, 3,4-DGE, GO, and MGO increased the production of reactive oxygen species and induced cell death. MGO induced cell death by apoptosis, whereas 3-DGal and 3,4-DGE induced nuclear translocation of the proinflammatory NF- κ B transcription pathway, and the activation of the pyroptosis-related NLRP3 inflammasome cascade. Overall, these results demonstrate the higher toxic impact of 1,2-dicarbonyl compounds on mucosal epithelial cells when compared to glycated amino acids and the selective activation of intracellular signaling pathways involved in the crosstalk mechanisms linking oxidative stress to excessive inflammation., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2021 Vanesa Cepas et al.)
- Published
- 2021
- Full Text
- View/download PDF
28. A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice.
- Author
-
Mohammad S, Al Zoubi S, Collotta D, Krieg N, Wissuwa B, Ferreira Alves G, Purvis GSD, Norata GD, Baragetti A, Catapano AL, Solito E, Zechendorf E, Schürholz T, Correa-Vargas W, Brandenburg K, Coldewey SM, Collino M, Yaqoob MM, Martin L, and Thiemermann C
- Subjects
- Animals, Diet, High-Fat adverse effects, Endotoxemia etiology, Endotoxemia metabolism, Humans, Male, Mice, Mice, Inbred C57BL, Cathelicidins, Antimicrobial Cationic Peptides metabolism, Antimicrobial Peptides pharmacology, Diabetes Mellitus, Type 2 metabolism, Inflammation etiology, Inflammation metabolism, Lipopolysaccharides antagonists & inhibitors
- Abstract
Metabolic endotoxemia has been suggested to play a role in the pathophysiology of metaflammation, insulin-resistance and ultimately type-2 diabetes mellitus (T2DM). The role of endogenous antimicrobial peptides (AMPs), such as the cathelicidin LL-37, in T2DM is unknown. We report here for the first time that patients with T2DM compared to healthy volunteers have elevated plasma levels of LL-37. In a reverse-translational approach, we have investigated the effects of the AMP, peptide 19-2.5, in a murine model of high-fat diet (HFD)-induced insulin-resistance, steatohepatitis and T2DM. HFD-fed mice for 12 weeks caused obesity, an impairment in glycemic regulations, hypercholesterolemia, microalbuminuria and steatohepatitis, all of which were attenuated by Peptide 19-2.5. The liver steatosis caused by feeding mice a HFD resulted in the activation of nuclear factor kappa light chain enhancer of activated B cells (NF-ĸB) (phosphorylation of inhibitor of kappa beta kinase (IKK)α/β, IκBα, translocation of p65 to the nucleus), expression of NF-ĸB-dependent protein inducible nitric oxide synthase (iNOS) and activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, all of which were reduced by Peptide 19-2.5. Feeding mice, a HFD also resulted in an enhanced expression of the lipid scavenger receptor cluster of differentiation 36 (CD36) secondary to activation of extracellular signal-regulated kinases (ERK)1/2, both of which were abolished by Peptide 19-2.5. Taken together, these results demonstrate that the AMP, Peptide 19-2.5 reduces insulin-resistance, steatohepatitis and proteinuria. These effects are, at least in part, due to prevention of the expression of CD36 and may provide further evidence for a role of metabolic endotoxemia in the pathogenesis of metaflammation and ultimately T2DM. The observed increase in the levels of the endogenous AMP LL-37 in patients with T2DM may serve to limit the severity of the disease., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Mohammad, Al Zoubi, Collotta, Krieg, Wissuwa, Ferreira Alves, Purvis, Norata, Baragetti, Catapano, Solito, Zechendorf, Schürholz, Correa-Vargas, Brandenburg, Coldewey, Collino, Yaqoob, Martin and Thiemermann.)
- Published
- 2021
- Full Text
- View/download PDF
29. Altered hepatic sphingolipid metabolism in insulin resistant mice: Role of advanced glycation endproducts.
- Author
-
Mastrocola R, Dal Bello F, Cento AS, Gaens K, Collotta D, Aragno M, Medana C, Collino M, Wouters K, and Schalkwijk CG
- Subjects
- Animals, Glycation End Products, Advanced, Liver, Mice, Mice, Inbred C57BL, Receptor for Advanced Glycation End Products genetics, Tandem Mass Spectrometry, Insulin, Sphingolipids
- Abstract
High plasma levels of the sphingolipid intermediates ceramide (Cer) and sphingosine-1-phosphate (S1P) are suggested to be involved in the development of insulin resistance (IR). Recent evidence indicates that advanced glycation endproducts (AGEs) can alter the sphingolipids metabolism equilibrium. Since enzymes responsible for sphingolipid rheostat maintenance are highly expressed in liver, we thus investigated whether AGEs accumulation can affect hepatic sphingolipids metabolism in insulin resistant mice. Two different models of IR were examined: genetically diabetic LeptrDb-/- (DbDb) and diet-induced insulin resistant C57Bl/6J mice fed a 60% trans-fat diet (HFD). In addition, a group of HFD mice was supplemented with the anti-AGEs compound pyridoxamine. AGEs were evaluated in the liver by western blotting. Cer and S1P were measured by UHPLC-MS/MS. The expression of RAGE and of enzymes involved in sphingolipid metabolism were assessed by RT-PCR and western blotting. HepG2 cells were used to study the effect of the major AGE Nε-(carboxymethyl)lysine (CML)-albumin on sphingolipid metabolism and the role of the receptor of AGEs (RAGE). High levels of AGEs and RAGE were detected in the liver of both DbDb and HFD mice in comparison to controls. The expression of enzymes of sphingolipid metabolism was altered in both models, accompanied by increased levels of Cer and S1P. Specifically, ceramide synthase 5 and sphingosine kinase 1 were increased, while neutral ceramidase was reduced. Pyridoxamine supplementation to HFD mice diminished hepatic AGEs and prevented alterations of sphingolipid metabolism and the development of IR. CML administration to HepG2 cells evoked alterations similar to those observed in vivo, that were in part mediated by the binding to RAGE. The present study shows a direct involvement of AGEs in alterations of sphingolipid metabolism associated to the development of IR. The modulation of sphingolipids metabolism through the prevention of AGEs accumulation by pyridoxamine may reduce the development of IR., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
30. Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock.
- Author
-
Sordi R, Chiazza F, Collotta D, Migliaretti G, Colas RA, Vulliamy P, Brohi K, Dalli J, Collino M, and Thiemermann C
- Subjects
- Animals, Biomarkers blood, Cytokines blood, Disease Models, Animal, Immunohistochemistry, Male, Multiple Organ Failure blood, Multiple Organ Failure etiology, Rats, Rats, Wistar, Shock, Hemorrhagic blood, Shock, Hemorrhagic complications, Docosahexaenoic Acids pharmacology, Multiple Organ Failure drug therapy, Shock, Hemorrhagic drug therapy
- Abstract
Objective: To evaluate the potential changes in the plasma levels of resolvin D1 (RvD1) in patients with trauma and hemorrhage. Having found that trauma results in a profound reduction in plasma RvD1 in patients, we have then investigated the effects of RvD1 on the organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat., Background: HS is a common cause of death in trauma due to excessive systemic inflammation and multiple organ failure. RvD1 is a member of the resolvin family of pro-resolution mediators., Methods: Blood samples were drawn from critically injured patients (n = 27, ACITII-prospective observational cohort study) within 2 hours of injury for targeted liquid chromatography tandem mass spectrometry. HS rats (removal of blood to reduce arterial pressure to 30 ± 2 mm Hg, 90 minutes, followed by resuscitation) were treated with RvD1 (0.3 or 1 μg/kg intravenous (i.v.)) or vehicle (n = 7). Parameters of organ injury and dysfunction were determined., Results: Plasma levels of RvD1 (mg/dL) were reduced in patients with trauma+HS (0.17 ± 0.08) when compared with healthy volunteers (0.76 ± 0.25) and trauma patients (0.62 ± 0.20). In rats with HS, RvD1 attenuated the kidney dysfunction, liver injury, and tissue ischemia. RvD1 also reduced activation of the nuclear factor (NF)-κB pathway and reduced the expression of pro-inflammatory proteins such as inducible nitric oxide synthase, tumor necrosis factor-α, interleukin-1β, and interleukin-6., Conclusion: Plasma RvD1 is reduced in patients with trauma-HS. In rats with HS, administration of synthetic RvD1 on resuscitation attenuated the multiple organ failure associated with HS by a mechanism that involves inhibition of the activation of NF-κB., Competing Interests: The authors have no conflicts of interest., (Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. D-Tagatose Feeding Reduces the Risk of Sugar-Induced Exacerbation of Myocardial I/R Injury When Compared to Its Isomer Fructose.
- Author
-
Durante M, Sgambellone S, Lucarini L, Failli P, Laurino A, Collotta D, Provensi G, Masini E, and Collino M
- Abstract
It is known that fructose may contribute to myocardial vulnerability to ischemia/reperfusion (I/R) injury. D-tagatose is a fructose isomer with less caloric value and used as low-calorie sweetener. Here we compared the metabolic impact of fructose or D-tagatose enriched diets on potential exacerbation of myocardial I/R injury. Wistar rats were randomizedly allocated in the experimental groups and fed with one of the following diets: control (CTRL), 30% fructose-enriched (FRU 30%) or 30% D-tagatose-enriched (TAG 30%). After 24 weeks of dietary manipulation, rats underwent myocardial injury caused by 30 min ligature of the left anterior descending (LAD) coronary artery followed by 24 h' reperfusion. Fructose consumption resulted in body weight increase (49%) as well as altered glucose, insulin and lipid profiles. These effects were associated with increased I/R-induced myocardial damage, oxidative stress (36.5%) and inflammation marker expression. TAG 30%-fed rats showed lower oxidative stress (21%) and inflammation in comparison with FRU-fed rats. Besides, TAG diet significantly reduced plasmatic inflammatory cytokines and GDF8 expression (50%), while increased myocardial endothelial nitric oxide synthase (eNOS) expression (59%). Overall, we demonstrated that D-tagatose represents an interesting sugar alternative when compared to its isomer fructose with reduced deleterious impact not only on the metabolic profile but also on the related heart susceptibility to I/R injury., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Durante, Sgambellone, Lucarini, Failli, Laurino, Collotta, Provensi, Masini and Collino.)
- Published
- 2021
- Full Text
- View/download PDF
32. Metabotropic Glutamate Receptor Blockade Reduces Preservation Damage in Livers from Donors after Cardiac Death.
- Author
-
Di Pasqua LG, Berardo C, Cagna M, Verta R, Collotta D, Nicoletti F, Ferrigno A, Collino M, and Vairetti M
- Subjects
- Animals, Liver Transplantation, Male, Rats, Rats, Wistar, Reperfusion Injury etiology, Reperfusion Injury pathology, Tissue Donors, Cold Ischemia adverse effects, Death, Liver metabolism, Organ Preservation methods, Receptors, Metabotropic Glutamate antagonists & inhibitors, Reperfusion Injury prevention & control, Warm Ischemia adverse effects
- Abstract
We previously demonstrated that the blockade of mGluR5 by 2-methyl-6(phenylethynyl)pyridine (MPEP) reduces both cold and warm ischemia/reperfusion injury. Here we evaluated whether MPEP reduces the hepatic preservation injury in rat livers from cardiac-death-donors (DCDs). Livers from DCD rats were isolated after an in situ warm ischemia (30 min) and preserved for 22 h at 4 °C with UW solution. Next, 10 mg/Kg MPEP or vehicle were administered 30 min before the portal clamping and added to the UW solution (3 µM). LDH released during washout was quantified. Liver samples were collected for iNOS, eNOS, NO, TNF-α, ICAM-1, caspase-3 and caspase-9 protein expression and nuclear factor-erythroid-2-related factor-2 (Nrf2) gene analysis. Lower LDH levels were detected in control grafts versus DCD groups. An increase in eNOS and NO content occurred after MPEP treatment; iNOS and TNF-α content was unchanged. ICAM-1 expression was reduced in the MPEP-treated livers as well as the levels of caspase-3 and caspase-9. Nrf2, oxidative stress-sensitive gene, was recovered to control value by MPEP. These results suggest that MPEP can be used to reclaim DCD livers subjected to an additional period of cold ischemia during hypothermic storage. MPEP protects against apoptosis and increased eNOS, whose overexpression has been previously demonstrated to be protective in hepatic ischemia/reperfusion damage.
- Published
- 2021
- Full Text
- View/download PDF
33. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
- Author
-
Bertocchi I, Foglietta F, Collotta D, Eva C, Brancaleone V, Thiemermann C, and Collino M
- Subjects
- Betacoronavirus isolation & purification, COVID-19, Coronavirus Infections immunology, Coronavirus Infections virology, Diabetes Mellitus epidemiology, Disease Progression, Drug Repositioning, Humans, Inflammation drug therapy, Inflammation immunology, Inflammation virology, NLR Family, Pyrin Domain-Containing 3 Protein immunology, Pandemics, Pneumonia, Viral immunology, Pneumonia, Viral virology, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, Coronavirus Infections drug therapy, Inflammasomes immunology, Obesity complications, Pneumonia, Viral drug therapy
- Abstract
COVID-19, the illness caused by SARS-CoV-2, has a wide-ranging clinical spectrum that, in the worst-case scenario, involves a rapid progression to severe acute respiratory syndrome and death. Epidemiological data show that obesity and diabetes are among the main risk factors associated with high morbidity and mortality. The increased susceptibility to SARS-CoV-2 infection documented in obesity-related metabolic derangements argues for initial defects in defence mechanisms, most likely due to an elevated systemic metabolic inflammation ("metaflammation"). The NLRP3 inflammasome is a master regulator of metaflammation and has a pivotal role in the pathophysiology of either obesity or diabetes. Here, we discuss the most recent findings suggesting contribution of NLRP3 inflammasome to the increase in complications in COVID-19 patients with diabesity. We also review current pharmacological strategies for COVID-19, focusing on treatments whose efficacy could be due, at least in part, to interference with the activation of the NLRP3 inflammasome. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc., (© 2020 The British Pharmacological Society.)
- Published
- 2020
- Full Text
- View/download PDF
34. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
- Author
-
O'Riordan CE, Purvis GSD, Collotta D, Krieg N, Wissuwa B, Sheikh MH, Ferreira Alves G, Mohammad S, Callender LA, Coldewey SM, Collino M, Greaves DR, and Thiemermann C
- Subjects
- Adenine analogs & derivatives, Adenine pharmacology, Animals, Benzamides pharmacology, Disease Models, Animal, Inflammasomes metabolism, Macrophages drug effects, Macrophages metabolism, Male, Mice, Mice, Inbred CBA, Multiple Organ Failure drug therapy, Phagocytosis drug effects, Piperidines pharmacology, Protein Kinase Inhibitors pharmacology, Pyrazines pharmacology, Sepsis drug therapy, X-Linked Combined Immunodeficiency Diseases drug therapy, Agammaglobulinaemia Tyrosine Kinase metabolism, Multiple Organ Failure metabolism, Sepsis metabolism, X-Linked Combined Immunodeficiency Diseases metabolism
- Abstract
We previously reported the Bruton's tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib improve outcomes in a mouse model of polymicrobial sepsis. Now we show that genetic deficiency of the BTK gene alone in Xid mice confers protection against cardiac, renal, and liver injury in polymicrobial sepsis and reduces hyperimmune stimulation ("cytokine storm") induced by an overwhelming bacterial infection. Protection is due in part to enhanced bacterial phagocytosis in vivo , changes in lipid metabolism and decreased activation of NF-κB and the NLRP3 inflammasome. The inactivation of BTK leads to reduced innate immune cell recruitment and a phenotypic switch from M1 to M2 macrophages, aiding in the resolution of sepsis. We have also found that BTK expression in humans is increased in the blood of septic non-survivors, while lower expression is associated with survival from sepsis. Importantly no further reduction in organ damage, cytokine production, or changes in plasma metabolites is seen in Xid mice treated with the BTK inhibitor ibrutinib, demonstrating that the protective effects of BTK inhibitors in polymicrobial sepsis are mediated solely by inhibition of BTK and not by off-target effects of this class of drugs., (Copyright © 2020 O'Riordan, Purvis, Collotta, Krieg, Wissuwa, Sheikh, Ferreira Alves, Mohammad, Callender, Coldewey, Collino, Greaves and Thiemermann.)
- Published
- 2020
- Full Text
- View/download PDF
35. Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation.
- Author
-
Purvis GSD, Collino M, Aranda-Tavio H, Chiazza F, O'Riordan CE, Zeboudj L, Mohammad S, Collotta D, Verta R, Guisot NES, Bunyard P, Yaqoob MM, Greaves DR, and Thiemermann C
- Subjects
- Animals, Glycogen Synthase Kinase 3 beta, Inflammation drug therapy, Macrophages, Male, Mice, Mice, Inbred C57BL, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, NF-kappa B
- Abstract
Background and Purpose: There are no medications currently available to treat metabolic inflammation. Bruton's tyrosine kinase (BTK) is highly expressed in monocytes and macrophages and regulates NF-κB and NLRP3 inflammasome activity; both propagate metabolic inflammation in diet-induced obesity., Experimental Approach: Using an in vivo model of chronic inflammation, high-fat diet (HFD) feeding, in male C57BL/6J mice and in vitro assays in primary murine and human macrophages, we investigated if ibrutinib, an FDA approved BTK inhibitor, may represent a novel anti-inflammatory medication to treat metabolic inflammation., Key Results: HFD-feeding was associated with increased BTK expression and activation, which was significantly correlated with monocyte/macrophage accumulation in the liver, adipose tissue, and kidney. Ibrutinib treatment to HFD-fed mice inhibited the activation of BTK and reduced monocyte/macrophage recruitment to the liver, adipose tissue, and kidney. Ibrutinib treatment to HFD-fed mice decreased the activation of NF-κB and the NLRP3 inflammasome. As a result, ibrutinib treated mice fed HFD had improved glycaemic control through restored signalling by the IRS-1/Akt/GSK-3β pathway, protecting mice against the development of hepatosteatosis and proteinuria. We show that BTK regulates NF-κB and the NLRP3 inflammasome specifically in primary murine and human macrophages, the in vivo cellular target of ibrutinib., Conclusion and Implications: We provide "proof of concept" evidence that BTK is a novel therapeutic target for the treatment of diet-induced metabolic inflammation and ibrutinib may be a candidate for drug repurposing as an anti-inflammatory agent for the treatment of metabolic inflammation in T2D and microvascular disease., (© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
- Published
- 2020
- Full Text
- View/download PDF
36. RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance.
- Author
-
Chen J, Purvis GSD, Collotta D, Al Zoubi S, Sugimoto MA, Cacace A, Martin L, Colas RA, Collino M, Dalli J, and Thiemermann C
- Subjects
- Animals, Bacterial Load drug effects, Biomarkers, Disease Models, Animal, Echocardiography, Eicosapentaenoic Acid pharmacology, Flow Cytometry, Gene Expression Regulation drug effects, Heart Diseases diagnosis, Heart Diseases drug therapy, Heart Diseases metabolism, Heart Function Tests, Immunity drug effects, Inflammation Mediators metabolism, Lipid Metabolism drug effects, Macrophages immunology, Macrophages metabolism, Mice, Models, Biological, Phagocytosis drug effects, Phagocytosis immunology, Prognosis, Sepsis immunology, Signal Transduction drug effects, Eicosapentaenoic Acid analogs & derivatives, Heart Diseases etiology, Sepsis complications, Sepsis microbiology
- Abstract
The development of cardiac dysfunction caused by microbial infection predicts high mortality in sepsis patients. Specialized pro-resolving mediators (SPMs) mediate resolution of inflammation in many inflammatory diseases, and are differentially expressed in plasma of sepsis patients. Here, we investigated whether the levels of SPMs are altered in the murine septic heart following polymicrobial sepsis-induced cardiac dysfunction. Ten weeks-old male C57BL/6 mice were subjected to polymicrobial sepsis induced by cecal ligation and puncture (CLP), which is a clinically relevant sepsis model receiving analgesics, antibiotics, and fluid resuscitation. CLP caused a significant systolic dysfunction assessed by echocardiography. The hearts were subjected to LC-MS/MS based lipid mediator profiling. Many SPMs were significantly reduced in septic hearts, among which RvE1 had a ~93-fold reduction. Treatment of CLP mice with synthetic RvE1 (1 μg/mouse i.v .) at 1 h after CLP increased peritoneal macrophages number, particularly MHC II
- macrophages. RvE1 reduced pro-inflammatory gene expression (interleukin-1β, interleukin-6, and CCL2) in lipopolysaccharide-stimulated bone marrow-derived macrophages (BMDMs) in vitro . RvE1 attenuated cardiac dysfunction in septic mice and increased cardiac phosphorylated Akt; decreased cardiac phosphorylated IκB kinase α/β, nuclear translocation of the NF-κB subunit p65, extracellular signal-regulated kinase 1/2, and c-Jun amino-terminal kinases 1/2. Most notably, RvE1 treatment reduced peritoneal bacterial load and promoted phagocytosis activity of BMDMs. In conclusion, cardiac SPMs, particularly RvE1, are substantially reduced in mice with polymicrobial sepsis. Delayed therapeutic administration of RvE1 to mice with polymicrobial sepsis attenuates the cardiac dysfunction through modulating immuno-inflammatory responses. In addition to the above effects, the ability to enhance bacterial clearance makes RvE1 an ideal therapeutic to reduce the sequalae of polymicrobial sepsis., (Copyright © 2020 Chen, Purvis, Collotta, Al Zoubi, Sugimoto, Cacace, Martin, Colas, Collino, Dalli and Thiemermann.)- Published
- 2020
- Full Text
- View/download PDF
37. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
- Author
-
Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Alves GF, Gaudioso G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiemermann C, and Collino M
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Biomarkers, Disease Models, Animal, Energy Metabolism drug effects, Gastrointestinal Microbiome drug effects, Glucose metabolism, Immunohistochemistry, Inflammation drug therapy, Inflammation etiology, Inflammation metabolism, Insulin metabolism, Janus Kinase 2 metabolism, Male, Metabolic Diseases diagnosis, Metabolic Diseases drug therapy, Mice, Muscle, Skeletal diagnostic imaging, Muscle, Skeletal drug effects, Muscle, Skeletal metabolism, STAT Transcription Factors metabolism, Signal Transduction drug effects, Azetidines pharmacology, Diet, High-Fat adverse effects, Janus Kinase Inhibitors pharmacology, Metabolic Diseases etiology, Metabolic Diseases metabolism, Purines pharmacology, Pyrazoles pharmacology, Sulfonamides pharmacology
- Abstract
Objective: Recent evidence suggests the substantial pathogenic role of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the development of low-grade chronic inflammatory response, known as "metaflammation," which contributes to obesity and type 2 diabetes. In this study, we investigated the effects of the JAK1/2 inhibitor baricitinib, recently approved for the treatment of rheumatoid arthritis, in a murine high-fat-high sugar diet model., Methods: Male C57BL/6 mice were fed with a control normal diet (ND) or a high-fat-high sugar diet (HD) for 22 weeks. A sub-group of HD fed mice was treated with baricitinib (10 mg/kg die, p.o.) for the last 16 weeks (HD + Bar)., Results: HD feeding resulted in obesity, insulin-resistance, hypercholesterolemia and alterations in gut microbial composition. The metabolic abnormalities were dramatically reduced by chronic baricitinib administration. Treatment of HD mice with baricitinib did not change the diet-induced alterations in the gut, but restored insulin signaling in the liver and skeletal muscle, resulting in improvements of diet-induced myosteatosis, mesangial expansion and associated proteinuria. The skeletal muscle and renal protection were due to inhibition of the local JAK2-STAT2 pathway by baricitinib. We also demonstrated that restored tissue levels of JAK2-STAT2 activity were associated with a significant reduction in cytokine levels in the blood., Conclusions: In summary, our data suggest that the JAK2-STAT2 pathway may represent a novel candidate for the treatment of diet-related metabolic derangements, with the potential for EMA- and FDA-approved JAK inhibitors to be repurposed for the treatment of type 2 diabetes and/or its complications., (Copyright © 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
38. Effects of Exogenous Dietary Advanced Glycation End Products on the Cross-Talk Mechanisms Linking Microbiota to Metabolic Inflammation.
- Author
-
Mastrocola R, Collotta D, Gaudioso G, Le Berre M, Cento AS, Ferreira Alves G, Chiazza F, Verta R, Bertocchi I, Manig F, Hellwig M, Fava F, Cifani C, Aragno M, Henle T, Joshi L, Tuohy K, and Collino M
- Subjects
- Animals, Cytokines metabolism, Ghrelin metabolism, Glucagon-Like Peptide 1 metabolism, Glucose metabolism, Glycosylation, Inflammation Mediators metabolism, Insulin metabolism, Mice, Inbred C57BL, Muscle, Skeletal metabolism, Signal Transduction, Diet, Gastrointestinal Microbiome, Glycation End Products, Advanced adverse effects, Glycation End Products, Advanced metabolism, Inflammation etiology, Inflammation metabolism, Metabolic Diseases etiology, Metabolic Diseases metabolism
- Abstract
Heat-processed diets contain high amounts of advanced glycation end products (AGEs). Here we explore the impact of an AGE-enriched diet on markers of metabolic and inflammatory disorders as well as on gut microbiota composition and plasma proteins glycosylation pattern. C57BL/6 mice were allocated into control diet (CD, n = 15) and AGE-enriched diet (AGE-D, n = 15) for 22 weeks. AGE-D was prepared replacing casein by methylglyoxal hydroimidazolone-modified casein. AGE-D evoked increased insulin and a significant reduction of GIP/GLP-1 incretins and ghrelin plasma levels, altered glucose tolerance, and impaired insulin signaling transduction in the skeletal muscle. Moreover, AGE-D modified the systemic glycosylation profile, as analyzed by lectin microarray, and increased Nε-carboxymethyllysine immunoreactivity and AGEs receptor levels in ileum and submandibular glands. These effects were associated to increased systemic levels of cytokines and impaired gut microbial composition and homeostasis. Significant correlations were recorded between changes in bacterial population and in incretins and inflammatory markers levels. Overall, our data indicates that chronic exposure to dietary AGEs lead to a significant unbalance in incretins axis, markers of metabolic inflammation, and a reshape of both the intestinal microbiota and plasma protein glycosylation profile, suggesting intriguing pathological mechanisms underlying AGEs-induced metabolic derangements.
- Published
- 2020
- Full Text
- View/download PDF
39. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades.
- Author
-
Penna C, Aragno M, Cento AS, Femminò S, Russo I, Bello FD, Chiazza F, Collotta D, Alves GF, Bertinaria M, Zicola E, Mercurio V, Medana C, Collino M, and Pagliaro P
- Subjects
- Animals, Humans, Male, Oxidation-Reduction, Platelet Aggregation Inhibitors pharmacology, Rats, Rats, Wistar, Ticagrelor pharmacology, Inflammasomes metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Platelet Aggregation Inhibitors therapeutic use, Ticagrelor therapeutic use
- Abstract
Inhibition of either P2Y12 receptor or the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain containing 3 (NLRP3) inflammasome provides cardioprotective effects. Here, we investigate whether direct NLRP3 inflammasome inhibition exerts additive effects on myocardial protection induced by the P2Y12 receptor antagonist Ticagrelor. Ticagrelor (150 mg/kg) was orally administered to rats for three consecutive days. Then, isolated hearts underwent an ischemia/reperfusion (30 min ischemia/60 min reperfusion; IR) protocol. The selective NLRP3 inflammasome inhibitor INF (50 μ M) was infused before the IR protocol to the hearts from untreated animals or pretreated with Ticagrelor. In parallel experiments, the hearts isolated from untreated animals were perfused with Ticagrelor (3.70 μ M) before ischemia and subjected to IR. The hearts of animals pretreated with Ticagrelor showed a significantly reduced infarct size (IS, 49 ± 3% of area at risk, AAR) when compared to control IR group (69 ± 2% of AAR). Similarly, ex vivo administration of INF before the IR injury resulted in significant IS reduction (38 ± 3% of AAR). Myocardial IR induced the NLRP3 inflammasome complex formation, which was attenuated by either INF pretreatment ex vivo , or by repeated oral treatment with Ticagrelor. The beneficial effects induced by either treatment were associated with the protective Reperfusion Injury Salvage Kinase (RISK) pathway activation and redox defence upregulation. In contrast, no protective effects nor NLRP3/RISK modulation were recorded when Ticagrelor was administered before ischemia in isolated heart, indicating that Ticagrelor direct target is not in the myocardium. Our results confirm that Ticagrelor conditioning effects are likely mediated through platelets, but are not additives to the ones achieved by directly inhibiting NLRP3., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2020 Claudia Penna et al.)
- Published
- 2020
- Full Text
- View/download PDF
40. Transient Expression of Reck Under Hepatic Ischemia/Reperfusion Conditions Is Associated with Mapk Signaling Pathways.
- Author
-
Ferrigno A, Di Pasqua LG, Palladini G, Berardo C, Verta R, Richelmi P, Perlini S, Collotta D, Collino M, and Vairetti M
- Subjects
- Animals, GPI-Linked Proteins metabolism, Male, Matrix Metalloproteinases metabolism, Nitric Oxide Synthase Type II metabolism, Nitric Oxide Synthase Type III metabolism, Rats, Wistar, Reperfusion Injury blood, Reperfusion Injury enzymology, Tissue Inhibitor of Metalloproteinases metabolism, Liver blood supply, Liver pathology, MAP Kinase Signaling System, Reperfusion Injury pathology, Tumor Suppressor Proteins metabolism
- Abstract
In this study, we demonstrated the involvement of matrix metalloproteinases (MMPs) in hepatic ischemia/reperfusion (I/R) injury. Our aim is to evaluate the impact of reperfusion on I/R-related changes in RECK, an MMP modulator, and mitogen-activated protein kinase (MAPKs) pathways (ERK, p38, and JNK). Male Wistar rats were either subjected to 60 min partial-hepatic ischemia or sham-operated. After a 60 min or 120 min reperfusion, liver samples were collected for analysis of MMP-2 and MMP-9 by zymography and RECK, TIMP-1, and TIMP-2 content, MAPKs activation (ERK1/2, JNK1/2, and p38), as well as iNOS and eNOS by Western blot. Serum enzymes AST, ALT, and alkaline-phosphatase were quantified. A transitory decrease in hepatic RECK and TIMPs was associated with a transitory increase in both MMP-2 and MMP-9 activity and a robust activation of ERK1/2, JNK1/2, and p38 were detected at 60 min reperfusion. Hepatic expression of iNOS was maximally upregulated at 120 min reperfusion. An increase in eNOS was detected at 120 min reperfusion. I/R evoked significant hepatic injury in a time-dependent manner. These findings provide new insights into the underlying molecular mechanisms of reperfusion in inducing hepatic injury: a transitory decrease in RECK and TIMPs and increases in both MAPK and MMP activity suggest their role as triggering factors of the organ dysfunction., Competing Interests: The authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
41. Ribonuclease 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of polymicrobial sepsis.
- Author
-
Zechendorf E, O'Riordan CE, Stiehler L, Wischmeyer N, Chiazza F, Collotta D, Denecke B, Ernst S, Müller-Newen G, Coldewey SM, Wissuwa B, Collino M, Simon TP, Schuerholz T, Stoppe C, Marx G, Thiemermann C, and Martin L
- Subjects
- Animals, Apoptosis physiology, Cardiomyopathies etiology, Carrier Proteins metabolism, Disease Models, Animal, Female, Humans, Male, Mice, Proteins metabolism, Sepsis complications, Cardiomyopathies metabolism, Cell-Free Nucleic Acids metabolism, Ribonuclease, Pancreatic metabolism, Sepsis metabolism
- Abstract
Septic cardiomyopathy is a life-threatening organ dysfunction caused by sepsis. Ribonuclease 1 (RNase 1) belongs to a group of host-defense peptides that specifically cleave extracellular RNA (eRNA). The activity of RNase 1 is inhibited by ribonuclease-inhibitor 1 (RNH1). However, the role of RNase 1 in septic cardiomyopathy and associated cardiac apoptosis is completely unknown. Here, we show that sepsis resulted in a significant increase in RNH1 and eRNA serum levels compared with those of healthy subjects. Treatment with RNase 1 resulted in a significant decrease of apoptosis, induced by the intrinsic pathway, and TNF expression in murine cardiomyocytes exposed to either necrotic cardiomyocytes or serum of septic patients for 16 hours. Additionally, treatment of septic mice with RNase 1 resulted in a reduction in cardiac apoptosis, TNF expression, and septic cardiomyopathy. These data demonstrate that eRNA plays a crucial role in the pathophysiology of the organ (cardiac) dysfunction in sepsis and that RNase and RNH1 may be new therapeutic targets and/or strategies to reduce the cardiac injury and dysfunction caused by sepsis.
- Published
- 2020
- Full Text
- View/download PDF
42. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
- Author
-
O'Riordan CE, Purvis GSD, Collotta D, Chiazza F, Wissuwa B, Al Zoubi S, Stiehler L, Martin L, Coldewey SM, Collino M, and Thiemermann C
- Subjects
- Adenine analogs & derivatives, Agammaglobulinaemia Tyrosine Kinase drug effects, Agammaglobulinaemia Tyrosine Kinase immunology, Animals, Benzamides pharmacology, Cecum, Disease Models, Animal, Inflammasomes drug effects, Inflammasomes immunology, Inflammasomes metabolism, Ligation, Male, Mice, Mice, Inbred C57BL, Piperidines, Punctures, Pyrazines pharmacology, Pyrazoles pharmacology, Pyrimidines pharmacology, Sepsis immunology, Sepsis metabolism, Agammaglobulinaemia Tyrosine Kinase metabolism, Heart drug effects, Heart Diseases etiology, Protein Kinase Inhibitors pharmacology, Sepsis complications
- Abstract
Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 inflammasome activation, two key components in the pathophysiology of sepsis and sepsis-associated cardiac dysfunction. In this study we investigated whether pharmacological inhibition of BTK (ibrutinib 30 mg/kg and acalabrutinib 3 mg/kg) attenuates sepsis associated cardiac dysfunction in mice. 10-week old male C57BL/6 mice underwent CLP or sham surgery. One hour after surgery mice received either vehicle (5% DMSO + 30% cyclodextrin i.v.), ibrutinib (30 mg/kg i.v.), or acalabrutinib (3 mg/kg i.v.). Mice also received antibiotics and an analgesic at 6 and 18 h. After 24 h, cardiac function was assessed by echocardiography in vivo . Cardiac tissue underwent western blot analysis to determine the activation of BTK, NLRP3 inflammasome and NF-κB pathway. Serum analysis of 33 cytokines was conducted by a multiplex assay. When compared to sham-operated animals, mice subjected to CLP demonstrated a significant reduction in ejection fraction (EF), fractional shortening (FS), and fractional area change (FAC). The cardiac tissue from CLP mice showed significant increases of BTK, NF-κB, and NLRP3 inflammasome activation. CLP animals resulted in a significant increase of serum cytokines and chemokines (TNF-α, IL-6, IFN-γ, KC, eotaxin-1, eotaxin-2, IL-10, IL-4, CXCL10, and CXCL11). Delayed administration of ibrutinib and acalabrutinib attenuated the decline of EF, FS, and FAC caused by CLP and also reduced the activation of BTK, NF-κB, and NLRP3 inflammasome. Both ibrutinib and acalabrutinib significantly suppressed the release of cytokines and chemokines. Our study revealed that delayed intravenous administration of ibrutinib or acalabrutinib attenuated the cardiac dysfunction associated with sepsis by inhibiting BTK, reducing NF-κB activation and the activation of the inflammasome. Cytokines associated with sepsis were significantly reduced by both BTK inhibitors. Acalabrutinib is found to be more potent than ibrutinib and could potentially prove to be a novel therapeutic in sepsis. Thus, the FDA-approved BTK inhibitors ibrutinib and acalabrutinib may be repurposed for the use in sepsis.
- Published
- 2019
- Full Text
- View/download PDF
43. Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes.
- Author
-
Purvis GSD, Collino M, Loiola RA, Baragetti A, Chiazza F, Brovelli M, Sheikh MH, Collotta D, Cento A, Mastrocola R, Aragno M, Cutrin JC, Reutelingsperger C, Grigore L, Catapano AL, Yaqoob MM, Norata GD, Solito E, and Thiemermann C
- Subjects
- Animals, Annexin A1 blood, Cholesterol blood, Diabetes Mellitus, Experimental therapy, Diabetes Mellitus, Type 2 therapy, Diet, High-Fat adverse effects, Dyslipidemias physiopathology, Fatty Liver blood, Fatty Liver pathology, Humans, Hyperglycemia physiopathology, Insulin Receptor Substrate Proteins metabolism, Insulin Resistance physiology, Mice, Mice, Inbred C57BL, Mice, Knockout, Obesity physiopathology, Receptors, Formyl Peptide metabolism, Receptors, Lipoxin metabolism, Annexin A1 genetics, Annexin A1 metabolism, Diabetes Mellitus, Experimental physiopathology, Diabetes Mellitus, Type 2 physiopathology, rhoA GTP-Binding Protein metabolism
- Abstract
Annexin A1 (ANXA1) is an endogenously produced anti-inflammatory protein, which plays an important role in the pathophysiology of diseases associated with chronic inflammation. We demonstrate that patients with type-2 diabetes have increased plasma levels of ANXA1 when compared to normoglycemic subjects. Plasma ANXA1 positively correlated with fatty liver index and elevated plasma cholesterol in patients with type-2 diabetes, suggesting a link between aberrant lipid handling, and ANXA1. Using a murine model of high fat diet (HFD)-induced insulin resistance, we then investigated (a) the role of endogenous ANXA1 in the pathophysiology of HFD-induced insulin resistance using ANXA1
-/- mice, and (b) the potential use of hrANXA1 as a new therapeutic approach for experimental diabetes and its microvascular complications. We demonstrate that: (1) ANXA1-/- mice fed a HFD have a more severe diabetic phenotype (e.g., more severe dyslipidemia, insulin resistance, hepatosteatosis, and proteinuria) compared to WT mice fed a HFD; (2) treatment of WT-mice fed a HFD with hrANXA1 attenuated the development of insulin resistance, hepatosteatosis and proteinuria. We demonstrate here for the first time that ANXA1-/- mice have constitutively activated RhoA. Interestingly, diabetic mice, which have reduced tissue expression of ANXA1, also have activated RhoA. Treatment of HFD-mice with hrANXA1 restored tissue levels of ANXA1 and inhibited RhoA activity, which, in turn, resulted in restoration of the activities of Akt, GSK-3β and endothelial nitric oxide synthase (eNOS) secondary to re-sensitization of IRS-1 signaling. We further demonstrate in human hepatocytes that ANXA1 protects against excessive mitochondrial proton leak by activating FPR2 under hyperglycaemic conditions. In summary, our data suggest that (a) ANXA1 is a key regulator of RhoA activity, which restores IRS-1 signal transduction and (b) recombinant human ANXA1 may represent a novel candidate for the treatment of T2D and/or its complications.- Published
- 2019
- Full Text
- View/download PDF
44. Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB.
- Author
-
Al Zoubi S, Chen J, Murphy C, Martin L, Chiazza F, Collotta D, Yaqoob MM, Collino M, and Thiemermann C
- Subjects
- Animals, Cecum microbiology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 etiology, Diabetes Mellitus, Type 2 immunology, Diet, High-Fat adverse effects, Disease Models, Animal, Humans, Linagliptin therapeutic use, Male, Mice, Mice, Inbred C57BL, NF-kappa B antagonists & inhibitors, NF-kappa B immunology, Piperidines pharmacology, Piperidines therapeutic use, Pyrrolidines pharmacology, Pyrrolidines therapeutic use, Sepsis complications, Sepsis etiology, Signal Transduction immunology, Diabetes Mellitus, Type 2 drug therapy, Heart Diseases immunology, Linagliptin pharmacology, NF-kappa B metabolism, Sepsis immunology, Signal Transduction drug effects
- Abstract
The mortality rate of patients who develop sepsis-related cardiac dysfunction is high. Many disease conditions (e.g., diabetes) increase the susceptibility to infections and subsequently sepsis. Activation of the NF-κB pathway plays a crucial role in the pathophysiology of sepsis-associated cardiac dysfunction and diabetic cardiomyopathy. The effect of diabetes on outcomes in patients with sepsis is still highly controversial. We here hypothesized that type 2 diabetes (T2DM) augments the cardiac (organ) dysfunction associated with sepsis, and that inhibition of the NF-κB pathway with linagliptin attenuates the cardiac (organ) dysfunction in mice with T2DM/sepsis. To investigate this, 10-week old male C57BL/6 mice were randomized to receive normal chow or high fat diet (HFD), 60% of calories derived from fat). After 12 weeks, mice were subjected to sham surgery or cecal ligation and puncture (CLP) for 24 h. At 1 hour after surgery, mice were treated with linagliptin (10 mg/kg, i.v.), IKK-16 (1 mg/kg, i.v.), or vehicle (2% DMSO, 3 ml/kg, i.v.). Mice also received analgesia, fluids and antibiotics at 6 and 18 h after surgery. Mice that received HFD showed a significant increase in body weight, impairment in glucose tolerance, reduction in ejection fraction (%EF), and increase in alanine aminotransferase (ALT). Mice on HFD subjected to CLP showed further reduction in %EF, increase in ALT, developed acute kidney dysfunction and lung injury. They also showed significant increase in NF-κB pathway, iNOS expression, and serum inflammatory cytokines compared to sham surgery group. Treatment of HFD-CLP mice with linagliptin or IKK-16 resulted in significant reductions in (i) cardiac, liver, kidney, and lung injury associated with CLP-sepsis, (ii) NF-κB activation and iNOS expression in the heart, and (iii) serum inflammatory cytokine levels compared to HFD-CLP mice treated with vehicle. Our data show that pre-existing type 2 diabetes phenotype worsens the organ dysfunction/injury associated with CLP-sepsis in mice. Most notably, inhibition of NF-κB reduces the organ dysfunction/injury associated with sepsis in mice with pre-existing T2DM.
- Published
- 2018
- Full Text
- View/download PDF
45. Reduced Susceptibility to Sugar-Induced Metabolic Derangements and Impairments of Myocardial Redox Signaling in Mice Chronically Fed with D-Tagatose when Compared to Fructose.
- Author
-
Collotta D, Lucarini L, Chiazza F, Cento AS, Durante M, Sgambellone S, Chini J, Baratta F, Aragno M, Mastrocola R, Masini E, and Collino M
- Subjects
- Animals, Heart drug effects, Male, Metabolic Syndrome chemically induced, Metabolic Syndrome metabolism, Mice, Mice, Inbred C57BL, Random Allocation, Signal Transduction drug effects, Sweetening Agents pharmacology, Fructose pharmacology, Hexoses pharmacology, Myocardium metabolism, Oxidation-Reduction drug effects, Oxidative Stress drug effects
- Abstract
Background: D-tagatose is an isomer of fructose and is ~90% as sweet as sucrose with less caloric value. Nowadays, D-tagatose is used as a nutritive or low-calorie sweetener. Despite clinical findings suggesting that D-tagatose could be beneficial in subjects with type 2 diabetes, there are no experimental data comparing D-tagatose with fructose, in terms of metabolic derangements and related molecular mechanisms evoked by chronic exposure to these two monosaccharides., Materials and Methods: C57Bl/6j mice were fed with a control diet plus water (CD), a control diet plus 30% fructose syrup (L-Fr), a 30% fructose solid diet plus water (S-Fr), a control diet plus 30% D-tagatose syrup (L-Tg), or a 30% D-tagatose solid diet plus water (S-Tg), during 24 weeks., Results: Both solid and liquid fructose feeding led to increased body weight, abnormal systemic glucose homeostasis, and an altered lipid profile. These effects were associated with vigorous increase in oxidative markers. None of these metabolic abnormalities were detected when mice were fed with both the solid and liquid D-tagatose diets, either at the systemic or at the local level. Interestingly, both fructose formulations led to significant Advanced Glycation End Products (AGEs) accumulation in mouse hearts, as well as a robust increase in both myocardial AGE receptor (RAGE) expression and NF- κ B activation. In contrast, no toxicological effects were shown in hearts of mice chronically exposed to liquid or solid D-tagatose., Conclusion: Our results clearly suggest that chronic overconsumption of D-tagatose in both formulations, liquid or solid, does not exert the same deleterious metabolic derangements evoked by fructose administration, due to differences in carbohydrate interference with selective proinflammatory and oxidative stress cascades.
- Published
- 2018
- Full Text
- View/download PDF
46. Fructose liquid and solid formulations differently affect gut integrity, microbiota composition and related liver toxicity: a comparative in vivo study.
- Author
-
Mastrocola R, Ferrocino I, Liberto E, Chiazza F, Cento AS, Collotta D, Querio G, Nigro D, Bitonto V, Cutrin JC, Rantsiou K, Durante M, Masini E, Aragno M, Cordero C, Cocolin L, and Collino M
- Subjects
- Animals, Feces chemistry, Fructose urine, Gastrointestinal Microbiome genetics, Gastrointestinal Microbiome physiology, Glucose Transporter Type 2 metabolism, Glycation End Products, Advanced metabolism, Inflammasomes metabolism, Lipid Metabolism drug effects, Liver Cirrhosis metabolism, Male, Metagenome drug effects, Mice, Inbred C57BL, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Fructose chemistry, Fructose toxicity, Gastrointestinal Microbiome drug effects, Liver Cirrhosis chemically induced
- Abstract
Despite clinical findings suggesting that the form (liquid versus solid) of the sugars may significantly affect the development of metabolic diseases, no experimental data are available on the impact of their formulations on gut microbiota, integrity and hepatic outcomes. In the present sudy, C57Bl/6j mice were fed a standard diet plus water (SD), a standard diet plus 60% fructose syrup (L-Fr) or a 60% fructose solid diet plus water (S-Fr) for 12 weeks. Gut microbiota was characterized through 16S rRNA phylogenetic profiling and shotgun sequencing of microbial genes in ileum content and related volatilome profiling. Fructose feeding led to alterations of the gut microbiota depending on the fructose formulation, with increased colonization by Clostridium, Oscillospira and Clostridiales phyla in the S-Fr group and Bacteroides, Lactobacillus, Lachnospiraceae and Dorea in the L-Fr. S-Fr evoked the highest accumulation of advanced glycation end products and barrier injury in the ileum intestinal mucosa. These effects were associated to a stronger activation of the lipopolysaccharide-dependent proinflammatory TLR4/NLRP3 inflammasome pathway in the liver of S-Fr mice than of L-Fr mice. In contrast, L-Fr intake induced higher levels of hepatosteatosis and markers of fibrosis than S-Fr. Fructose-induced ex novo lipogenesis with production of SCFA and MCFA was confirmed by metagenomic analysis. These results suggest that consumption of fructose under different forms, liquid or solid, may differently affect gut microbiota, thus leading to impairment in intestinal mucosa integrity and liver homeostasis., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
47. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways.
- Author
-
Mastrocola R, Penna C, Tullio F, Femminò S, Nigro D, Chiazza F, Serpe L, Collotta D, Alloatti G, Cocco M, Bertinaria M, Pagliaro P, Aragno M, and Collino M
- Subjects
- Animals, Energy Metabolism drug effects, Enzyme-Linked Immunosorbent Assay, In Vitro Techniques, Inflammasomes metabolism, Interleukin-1beta metabolism, L-Lactate Dehydrogenase metabolism, Male, Myocardial Contraction, Myocardial Ischemia pathology, Myocardial Ischemia physiopathology, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Organelle Biogenesis, Rats, Wistar, Inflammasomes antagonists & inhibitors, Mitochondria metabolism, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, NLR Family, Pyrin Domain-Containing 3 Protein antagonists & inhibitors, Protein Kinases metabolism, Signal Transduction
- Abstract
Although the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain containing 3 (NLRP3) inflammasome has been recently detected in the heart, its role in cardiac ischemia/reperfusion (IR) is still controversial. Here, we investigate whether a pharmacological modulation of NLRP3 inflammasome exerted protective effects in an ex vivo model of IR injury. Isolated hearts from male Wistar rats (5-6 months old) underwent ischemia (30 min) followed by reperfusion (20 or 60 min) with and without pretreatment with the recently synthetized NLRP3 inflammasome inhibitor INF4E (50 μ M, 20 min before ischemia). INF4E exerted protection against myocardial IR, shown by a significant reduction in infarct size and lactate dehydrogenase release and improvement in postischemic left ventricular pressure. The formation of the NLRP3 inflammasome complex was induced by myocardial IR and attenuated by INF4E in a time-dependent way. Interestingly, the hearts of the INF4E-pretreated animals displayed a marked improvement of the protective RISK pathway and this effect was associated increase in expression of markers of mitochondrial oxidative phosphorylation. Our results demonstrate for the first time that INF4E protected against the IR-induced myocardial injury and dysfunction, by a mechanism that involves inhibition of the NLRP3 inflammasome, resulting in the activation of the prosurvival RISK pathway and improvement in mitochondrial function., Competing Interests: The authors declare that they have no competing interests.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.